The global surgical site infection prevention market is growing at a significant phase i.e., at a 6.5% CAGR during 2021-2027 owing to the rising hospital-acquired infections and increasing number of surgeries will drive the market. Moreover, the increased emphasis on preventing surgical site infection via appropriate measures in emerging regions and the growing geriatric population will propel the growth in the global surgical site infection prevention market. Surgical site infections can be superficial, deep incisional, and organ-related.

The World Health Organization has started an awareness program named Patient Safety Solutions which requires proper hand hygiene to decrease the occurrence of infectious diseases. Thus, the increasing initiatives by WHO will create healthcare awareness and increase the demand for the global surgical site infection prevention market.

Request to get a free sample copy at https://www.vynzresearch.com/healthcare/surgical-site-infection-prevention-market/request-sample

Based on the product, antibiotic prophylaxis contributes to the largest share as it is the utmost common form of preventive measure in healthcare facilities to prevent infection and contamination during the treatment process.

Based on phase, intraoperative phase dominates the market owing to the increased volume of products required to reduce the chances of infection and adherence od medical professionals to follow infection control guidelines set by WHO.

North America dominates the global surgical site infection prevention market due to the well-established healthcare infrastructure, presence of prominent surgical site infection manufacturers, increasing awareness of this infection in the region. Furthermore, the rising geriatric population and successive increase in the number of surgeries will further drive the growth in the region.

3M is on the mission to protect patients from preventable surgical site infections (SSIs) as they believe that up to 5% of patients undergoing surgery may have negative consequences of an SSI, as patients might have an increased length of stay in hospital that can impact the quality of life. So they are committed to using their best practices and evidence-based solutions to reduce the risk of SSIs in the facility.

The prominent players in the surgical site infection prevention industry include 3M Company, Medtronic plc, Mölnlycke Health Care AB, B. Braun Melsungen AG, Covalon Technologies Ltd., Stryker Corporation, Becton, Dickinson and Company, Prescient Surgical Inc., Surgical Site Infection Prevention LLC, and STERIS plc.

Source VynZ Research